Patents-Review.com
ClassID:

20200 ⎘

A61K31/06 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates; Phenols the aromatic ring being substituted by nitro groups

Recent Application in this class:
#1
20260108476
2026-04-23

2,4 DNP and Prodrugs Thereof for Treatment of Cancer

 #2
20260083686
2026-03-26

METHODS FOR SUPPRESSING ACCUMULATION OF REFLUX-INDUCED PROTEIN ADDUCTS

 #3
20250302825
2025-10-02

COMBINATION TREATMENTS FOR DEPRESSION UTILIZING AN NMDAR ANTAGONIST

 #4
20250228793
2025-07-17

2,4-Dinitrophenol Formulations and Methods Using Same

 #5
20250144090
2025-05-08

COMPOSITION AND METHOD FOR TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS

 #6
20240207202
2024-06-27

COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY

 #7
20240156750
2024-05-16

Induced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic Diseases

 #8
20240148670
2024-05-09

ANTIMICROBIAL ADJUVANT CONTAINING BIPHENYL DERIVATIVE COMPOUND AS ACTIVE INGREDIENT, AND USES THEREOF

 #9
20230272077
2023-08-31

PD-1 SIGNAL INHIBITOR COMBINATION THERAPY

 #10
20230265193
2023-08-24

PD-1 SIGNAL INHIBITOR COMBINATION THERAPY

 #11
20230255995
2023-08-17

Nicotinyl Riboside Compounds and Their Uses

 #12
20230201193
2023-06-29

COMPOSITION AND METHOD FOR TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS

 #13
20230181489
2023-06-15

COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY

 #14
20230100940
2023-03-30

DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases

 #15
20230049807
2023-02-16

PHARMACEUTICAL COMPOSITION COMPRISING TRANS - CINNAMALDEHYDE AND ITS USE IN THE TREATMENT OF INFECTIONS

 #16
20220339121
2022-10-27

2,4-dinitrophenol formulations and methods using same

 #17
20220323435
2022-10-13

COMPOSITION AND METHOD FOR TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS

 #18
20220280460
2022-09-08

METHODS AND COMPOSITIONS FOR STIMULATING EXOSOME SECRETION

 #19
20220175704
2022-06-09

Sensitization of cancer cells to differentiation therapy with mitochondrial uncoupler niclosamide ethanolamine

 #20
20210161937
2021-06-03

ACTIVATION OF MITOCHONDRIAL UNCOUPLING AS A THERAPEUTIC INTERVENTION

 #21
20210052513
2021-02-25

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

 #22
20200397807
2020-12-24

NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES

 #23
20200397676
2020-12-24

Cosmetic compositions and methods of use

 #24
20200352879
2020-11-12

2,4-dinitrophenol formulations and methods using same

 #25
20200333339
2020-10-22

Blood cell biomarker for late onset Alzheimer's disease

 #26
20200206219
2020-07-02

Composition and method for treatment of depression and psychosis in humans

 #27
20200197323
2020-06-25

METHODS FOR SUPPRESSING ACCUMULATION OF REFLUX-INDUCED PROTEIN ADDUCTS

 #28
20200093831
2020-03-26

DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases

 #29
20200003782
2020-01-02

Nanoparticles for mitochondrial trafficking of agents

 #30
20190175524
2019-06-13

Method, compositions and device for nano-enhanced opto-chemical trans-differentiation of cells and tissues

 #31
20190142765
2019-05-16

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

 #32
20190125778
2019-05-02

Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy

 #33
20190076406
2019-03-14

METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR

 #34
20190054085
2019-02-21

COMPOSITION AND METHOD FOR TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS

 #35
20180362650
2018-12-20

PD-1 SIGNAL INHIBITOR COMBINATION THERAPY

 #36
20180338972
2018-11-29

Anthelmintic compounds

 #37
20180311184
2018-11-01

TOPICAL ANALGESIC PAIN RELIEF FORMULATIONS, MANUFACTURE AND METHODS OF USE THEREOF

 #38
20180263976
2018-09-20

Composition and method for treatment of depression and psychosis in humans

 #39
20180228740
2018-08-16

COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY

 #40
20180125794
2018-05-10

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of Neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

 #41
20180000791
2018-01-04

METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR

 #42
20170312275
2017-11-02

Composition and method for treatment of depression and psychosis in humans

 #43
20170252347
2017-09-07

DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases

 #44
20170100394
2017-04-13

Anthelmintic compounds

 #45
20170065536
2017-03-09

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

 #46
20160333025
2016-11-17

Method for preparing curable bicyclic compound derived from biomass

 #47
20160296479
2016-10-13

Pharmaceutical composition comprising trans-cinnamaldehyde and its use in the treatment of infections

 #48
20160213625
2016-07-28

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

 #49
20160199310
2016-07-14

2,4-dinitrophenol formulations and methods using same

 #50
20160022825
2016-01-28

Nanoparticles for mitochondrial trafficking of agents

 #51
20160008332
2016-01-14

Combinatorial compositions and methods for treatment of melanoma

 #52
20150374684
2015-12-31

Composition and method for treatment of depression and psychosis in humans

 #53
20150225426
2015-08-13

Anti-cancer agents and methods of use

 #54
20150056160
2015-02-26

CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA

 #55
20150050327
2015-02-19

Liposome formulation suitable for treating or preventing tuberculosis

 #56
20140066637
2014-03-06

Method for preparing curable bicyclic compound derived from biomass

 #57
20140037695
2014-02-06

Compositions and methods for targeting of treating neoplasms

 #58
20140018348
2014-01-16

Composition and method for treatment of depression and psychosis in humans

 #59
20130316985
2013-11-28

GPR35 Ligands And Uses Thereof

 #60
20130131001
2013-05-23

Epirubicin derivatives

 #61
20120277175
2012-11-01

PHARMACEUTICAL COMBINATIONS, PHARMACEUTICAL COMPOSITIONS, MEDICAMENT AND METHOD FOR THE TREATMENT OF ANIMALS

 #62
20120276111
2012-11-01

METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR

 #63
20120252996
2012-10-04

Curable Bicyclic Compound Derived from Biomass, Solvent-Free Curable Composition, and Method for Preparing Same

 #64
20110135580
2011-06-09

Novel Medicament Combinations for the Treatment of Respiratory Diseases

 #65
20110130468
2011-06-02

Hydroxylated tolans and related compounds in the treatment of a cancer

 #66
20110027251
2011-02-03

NOVEL USES FOR 4-PHENYLBUTYRATE (4PBA) AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

 #67
20100210898
2010-08-19

MAMMALIAN REPRODUCTION

 #68
20100160403
2010-06-24

HCV NS3 PROTEASE INHIBITORS

 #69
20100129472
2010-05-27

Compositions And Method For The Treatment Of Acne

 #70
20100104660
2010-04-29

Targeting cancer therapy combination

 #71
20100087405
2010-04-08

FOOD SUPPLEMENTATION COMPOSITION CONTAINING ONE OR MORE VITAMIN D3 COMPOUNDS AND ONE OR MORE MAGNESIUM SALTS

 #72
20100056643
2010-03-04

CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA

 #73
20100041631
2010-02-18

METHODS AND AGENTS FOR TREATING TUBERCULOSIS

 #74
20090238895
2009-09-24

NUTRITIONAL AND/OR PHARMACEUTICAL PREPARATION FOR USE IN PROPHYLAXIS AND TREATMENT OF DISTURBANCES IN MICROELEMENTS ABSORPTION FROM THE ALIMENTARY CANAL

 #75
20090170770
2009-07-02

METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP 1) INHIBITOR

 #76
20090169648
2009-07-02

COMPOSITIONS TO REDUCE BLOOD GLUCOSE LEVELS AND TREAT DIABETES

 #77
20090123386
2009-05-14

Abuse Resistant Capsules

 #78
20090075918
2009-03-19

Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectin and/or milbemycin

 #79
20090010884
2009-01-08

PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION

 #80
20070292478
2007-12-20

Medical Implant Provided with Inhibitors of Atp Synthesis

 #81
20070254047
2007-11-01

COMPOSITIONS TO REDUCE BLOOD GLUCOSE LEVELS AND TREAT DIABETES

 #82
20070184047
2007-08-09

Nitrophenyls and related compounds and thimerosal for the inhibition of immune related cell or tissue destruction

 #83
20060264531
2006-11-23

Biodegradable medical devices with enhanced mechanical strength and pharmacological functions

 #84
20060142358
2006-06-29

Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes

 #85
20060052456
2006-03-09

Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells

 #86
20050266098
2005-12-01

Composition for treatment of a hydrofluoric acid burn